title: Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
abstract: We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
authors.affiliation: From the *Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; †Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; ‡Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand: §Nakornping Hospital, Chiang Mai, Thailand; ¶The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), the Thai Red Cross AIDS Research, Bangkok, Thailand; and ‖Department of Pediatrics, Faculty of Medicine, and Research Unit in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Linda
authors.initials: L
authors.lastname: Aurpibul
authors.forename: Pagakrong
authors.initials: P
authors.lastname: Lumbiganon
authors.forename: Rawiwan
authors.initials: R
authors.lastname: Hansudewechakul
authors.forename: Suparat
authors.initials: S
authors.lastname: Kanjanavanit
authors.forename: Torsak
authors.initials: T
authors.lastname: Bunupuradah
authors.forename: Pope
authors.initials: P
authors.lastname: Kosalaraksa
authors.forename: Pawinee
authors.initials: P
authors.lastname: Taeprasert
authors.forename: Thanyawee
authors.initials: T
authors.lastname: Puthanakit
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D060085:Coinfection / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006509:Hepatitis B / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008137:Longitudinal Studies; D011446:Prospective Studies; D000068698:Tenofovir / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine; D000068698:Tenofovir